Brick & Kyle Associates’s Gilead Sciences GILD Stock Holding History

Brick & Kyle Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-592	Closed	-$40K	–	192
2017 Q1	$40K	Sell	592 -22,047	-97%	-$1.55M	0.03%	201
2016 Q4	$1.62M	Buy	22,639 +560	+3%	+$41.6K	1.3%	32
2016 Q3	$1.75M	Sell	22,079 -157	-0.7%	-$12.8K	1.4%	29
2016 Q2	$1.85M	Sell	22,236 -297	-1%	-$26.4K	1.52%	25
2016 Q1	$2.07M	Sell	22,533 -97	-0.4%	-$8.75K	1.8%	18
2015 Q4	$2.29M	Sell	22,630 -650	-3%	-$67.6K	2.02%	11
2015 Q3	$2.29M	Buy	23,280 +750	+3%	+$83.3K	2.15%	9
2015 Q2	$2.64M	Buy	22,530 +400	+2%	+$43.7K	2.21%	9
2015 Q1	$2.17M	Buy	22,130 +2,530	+13%	+$257K	1.86%	13
2014 Q4	$1.85M	Buy	+19,600	New	+$2.03M	1.59%	20

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brick & Kyle Associates's GILD Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 592 shares — an estimated $40K sold.

Brick & Kyle Associates first reported a position in GILD in Q4 2014 and held it in 10 quarters. The position peaked at $2.64M in Q2 2015. 1,520 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

Brick & Kyle Associates reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 592 Gilead Sciences shares in Q2 2017, an estimated $40K.
Brick & Kyle Associates first reported a position in Gilead Sciences in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's Gilead Sciences position peaked at $2.64M in Q2 2015.
1,520 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.